Predicting the Spread of Prostate Cancer with the Assistance of Stromal Cells

The

Researchers at Weill Cornell Medicine have conducted a study revealing the potential significance of non-cancerous stromal cells, commonly found in and around prostate tumors. These cells, known for their role in wound healing and tissue support, may serve as indicators for assessing a tumor's likelihood to spread. Moreover, they could become targets for future prostate cancer treatments.

The study, published in Nature Communications on January 8, marks the most comprehensive analysis to date of stromal cells in and around prostate tumors. By examining mouse models and human patient samples, the researchers identified eight subpopulations of stromal cells, each exhibiting distinct patterns of gene activity associated with tumors. Changes in these patterns were found to predict tumor spread, or metastasis.

The research also uncovered signaling interactions among stromal cells, tumor cells, and nearby immune cells, suggesting potential targets for preventing metastasis. Dr. Massimo Loda, the senior author of the study, emphasized the impact of stromal cells on prostate cancer progression and the potential for new prognostic and therapeutic strategies.

Tumor progression is not only driven by mutations in cancerous cells but also by changes in non-cancerous cells induced and supported by tumors. While previous research focused on immune cells within the tumor microenvironment, the supportive activities of stromal cells have gained attention. In 2017, Dr. Loda's team discovered a gene activity signature in prostate cancer stromal cells associated with metastasis.

Using advanced techniques such as single-cell RNA sequencing and AI-based analysis, the researchers identified major subpopulations of tumor-associated stromal cells in both mouse and human tumors. Changes in these cells were observed with the acquisition of cancer-driving mutations and the progression to metastasis. Remarkably, stromal cells surrounding prostate tumors were found to create an environment resembling bone, potentially preparing the tumor cells to spread to bones—a common site for prostate cancer metastasis.

The analysis unveiled lists of signaling proteins and networks that become active or inactive during these changes, providing potential targets for future prostate cancer treatments. Dr. Loda and his team aim to develop prognostic tests on tumor-associated stromal cells to predict the aggressiveness of prostate tumors, aiding physicians in making better treatment choices.

The potential application of such tests on biopsy samples, even in the absence of visible tumor tissue, could provide valuable insights into the likelihood of tumor existence and its aggressiveness, prompting further investigation if necessary.